HeartBeam Q2 slides show clinical progress despite wider Q2 2026 loss

HeartBeam Inc. (NASDAQ:BEAT) released its second-quarter 2026 financial results on August 13, demonstrating clinical progress while reporting a much larger net loss than anticipated. The cardiac monitoring technology company's stock rose initially before sliding back after hours. HeartBeam is focusing on a portable 12-lead ECG platform aimed at a $40 billion cardiac monitoring market, with a particular emphasis on expanding indications for heart attack detection.

Although the company showcased improved cash discipline and clinical momentum, the earnings per share of negative $1.10 significantly underperformed analyst expectations, which stood at negative $0.09 per share. The company's second-quarter financials revealed a net loss of $5.0 million, a decrease of 17% from the second quarter of the previous year and an improvement of 12% from the first quarter of 2026.

However, excluding $0.9 million in one-time items, the underlying net loss was approximately $4.1 million. Chief Financial Officer Tim Cruickshank highlighted the company's focus on cost management, with operating cash flow decreasing by 7% from the first quarter to $3.3 million. The company expects full-year 2026 operating cash outflow to remain below $14.0 million, with the fourth quarter's cash flow projected to drop below $2.5 million per quarter.

HeartBeam made substantial progress on its heart attack detection program, advancing multiple clinical studies ahead of schedule. The ALIGN-ACS pilot study completed enrollment in less than four months and will present results at the TCT 2026 conference in San Diego. Meanwhile, the HEADSTART-ACS pilot study surpassed 50% enrollment in under three months, evaluating the accuracy of HeartBeam's ECG technology in detecting heart attacks in real-world settings.

The company has initiated a patch pilot study evaluating its 12-lead ECG patch in approximately 50 patients with high risk of coronary artery disease. HeartBeam submitted a pre-submission package to the FDA and plans to pursue a 510(k) regulatory pathway for its heart attack detection indication.